212 related articles for article (PubMed ID: 38401888)
1. PD-1 regulation in immune homeostasis and immunotherapy.
Gao M; Shi J; Xiao X; Yao Y; Chen X; Wang B; Zhang J
Cancer Lett; 2024 Apr; 588():216726. PubMed ID: 38401888
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy.
Jiang Y; Hong K; Zhao Y; Xu K
Front Immunol; 2023; 14():1228200. PubMed ID: 37415977
[TBL] [Abstract][Full Text] [Related]
3. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment.
Parvez A; Choudhary F; Mudgal P; Khan R; Qureshi KA; Farooqi H; Aspatwar A
Front Immunol; 2023; 14():1296341. PubMed ID: 38106415
[TBL] [Abstract][Full Text] [Related]
4. [Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy].
Su Y; Wang Q; Ru Y; Dong J; Li X; Zhang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Nov; 38(11):1036-1043. PubMed ID: 36328434
[TBL] [Abstract][Full Text] [Related]
5. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
[TBL] [Abstract][Full Text] [Related]
6. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
Ni JM; Ni AP
Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108
[TBL] [Abstract][Full Text] [Related]
7. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
Ai L; Xu A; Xu J
Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
[TBL] [Abstract][Full Text] [Related]
8. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy.
Xiong W; Gao Y; Wei W; Zhang J
Trends Cancer; 2021 Sep; 7(9):837-846. PubMed ID: 33903073
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.
Liu M; Sun Q; Wei F; Ren X
Cancer Biol Med; 2020 Aug; 17(3):626-639. PubMed ID: 32944395
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumour potential of PD-L1/PD-1 post-translational modifications.
Zhou S; Zhu J; Xu J; Gu B; Zhao Q; Luo C; Gao Z; Chin YE; Cheng X
Immunology; 2022 Dec; 167(4):471-481. PubMed ID: 36065492
[TBL] [Abstract][Full Text] [Related]
11. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
[TBL] [Abstract][Full Text] [Related]
12. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy.
Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
[TBL] [Abstract][Full Text] [Related]
13. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.
Shen X; Zhang L; Li J; Li Y; Wang Y; Xu ZX
Front Immunol; 2019; 10():1337. PubMed ID: 31258527
[TBL] [Abstract][Full Text] [Related]
14. Generation, secretion and degradation of cancer immunotherapy target PD-L1.
Shen DD; Bi YP; Pang JR; Zhao LJ; Zhao LF; Gao Y; Wang B; Liu HM; Liu Y; Wang N; Zheng YC; Liu HM
Cell Mol Life Sci; 2022 Jul; 79(8):413. PubMed ID: 35819633
[TBL] [Abstract][Full Text] [Related]
15. Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy.
García-Aranda M; Redondo M
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31075880
[TBL] [Abstract][Full Text] [Related]
16. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
17. Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy.
Li JH; Huang LJ; Zhou HL; Shan YM; Chen FM; Lehto VP; Xu WJ; Luo LQ; Yu HJ
Acta Pharmacol Sin; 2022 Nov; 43(11):2749-2758. PubMed ID: 35484402
[TBL] [Abstract][Full Text] [Related]
18. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
[TBL] [Abstract][Full Text] [Related]
19. Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape.
Cui JW; Li Y; Yang Y; Yang HK; Dong JM; Xiao ZH; He X; Guo JH; Wang RQ; Dai B; Zhou ZL
Biomed Pharmacother; 2024 Feb; 171():116203. PubMed ID: 38280330
[TBL] [Abstract][Full Text] [Related]
20. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Wang Y; Ma R; Liu F; Lee SA; Zhang L
Front Immunol; 2018; 9():374. PubMed ID: 29556232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
